DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Walmart, Lowe's, Intuit, Kraft Heinz and more
▼ + stars: | 2024-11-19 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: Walmart — The big-box retailer saw shares jump nearly 5% to hit a record after the retail giant topped fiscal third-quarter earnings and revenue expectations. The retailer also hiked its outlook again as it saw growth in e-commerce and improvements in sales outside of the grocery aisles. Lowe's — The home improvement retailer dropped more than 3% after saying it expects sales to decline in 2024 . Kraft Heinz — The packaged food company dipped about 1% after a Piper Sandler downgrade to neutral from overweight. Insmed — Shares rallied more than 8% after the drugmaker terminated a $500 million equity sales agreement with health-care investment bank Leerink Partners.

Persons: Young, Lowe's, Kraft Heinz —, Piper Sandler, Kraft Heinz, Robert F, Kennedy Jr, Trump, —, Wall, Symbotic, Donald Trump's, Jesse Pound, Yun Li, Sarah Min, Alex Harring, Sean Conlon, Pia Singh Organizations: Walmart, BDO, Ernst, Nasdaq, Leerink Partners, Viking Holdings, Revenue, Intuit, Washington Post, Donald Trump's Department, Government

☆ Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
▼ + stars: | 2024-11-09 | by ( Kenneth Squire | ) www.cnbc.com time to read: +7 min

It invests in a concentrated portfolio of small and midcap life sciences companies, using activism as a tool to unlock value. A successful drug like Ohtuvayre would not just increase the life expectancies of patients with COPD, but it would lower costs for both health-care providers and COPD patients. Currently, there are over 8.6 million U.S. COPD patients with over 4 million remaining symptomatic despite treatment from the current commercial therapies. In early pooling analysis, Ohtuvayre showed a 41% reduction in exacerbations in COPD patients, almost double brensocatib. When Caligan announced its Verona position last month, the stock was trading at $33.40 per share or a $2.5 billion enterprise value.

Persons: Caligan, David Johnson, Ohtuvayre, Verona's, Verona, MorphoSys, bode, Ken Squire Organizations: Verona Pharma, Caligan Partners, Carlyle Group, FDA, MorphoSys AG, Novartis, pharma, 13D Locations: Verona, London, MorphoSys, Caligan's

☆ Cramer's Lighting Round: Amazon 'has a lot of room to go higher'
▼ + stars: | 2024-06-03 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Amazon's year-to-date stock performance. Stock Chart Icon Stock chart icon Forward Air's year-to-date stock performance. Stock Chart Icon Stock chart icon Ingersoll Rand's year-to-date stock performance. Stock Chart Icon Stock chart icon Cracker Barrel's year-to-date stock performance. Stock Chart Icon Stock chart icon Insmed's year-to-date stock performance.

Persons: They've, Ingersoll, Ingersoll Rand, Jim Cramer's Organizations: Forward

☆ Insmed CEO on lung disease treatment and path forward
▼ + stars: | 2024-05-28 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailInsmed CEO on lung disease treatment and path forwardWill Lewis, Insmed CEO, joins 'Fast Money' to talk its latest lung disease treatment, growth opportunity and more.

Persons: Will Lewis

☆ Chart of the Day: Insmed
▼ + stars: | 2024-05-28 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailChart of the Day: InsmedMichelle Ross, StemPoint Capital Chief Investment Officer & Managing Parter, joins us with the latest on the stock and a few more biotech names she's watching.

Persons: Insmed Michelle Ross

☆ Stocks making the biggest moves midday: GameStop, U.S. Cellular, Nvidia, Norwegian Cruise Line and more
▼ + stars: | 2024-05-28 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Check out the companies making the biggest moves midday: GameStop — Shares jumped nearly 23% following the video game retailer's announcement on Friday that it made about $933 million from a stock sale. U.S. Cellular — Shares added 7% after the telecom company announced T-Mobile will acquire its wireless operations and 30% of spectrum assets for $4.4 billion. T-Mobile was up less than 1%, while Telephone and Data Systems , which owns 84% of U.S. Cellular, slipped 2%. Norwegian Cruise Line — The cruise stock rose 3% after an upgrade to buy from neutral at Mizuho. Zscaler — The cybersecurity company shed nearly 4% following a downgrade at Wells Fargo to equal weight from overweight.

Persons: Agios, vorasidenib, —, Duolingo Max, Semler, Elon, Zscaler, Airbnb, Eli Lilly, Macheel, Pia Singh, Hakyung Kim, Jesse Pound Organizations: GameStop, . Illinois, U.S, Cellular, Mobile, Telephone, Data Systems, U.S . Cellular, . Food, Drug, Pharmaceuticals, Royalty Pharma, Nvidia, Cruise, Mizuho, Sarepta Therapeutics, RBC Capital Markets, RBC, Sea, Reuters, —, Energy Capital Partners, Wedbush, FDA Locations: U.S, Norwegian, Wells

☆ Here are Wells Fargo's top trades for the second quarter
▼ + stars: | 2024-04-02 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

The second quarter is underway, and Wells Fargo has laid out its top stock ideas to maximize investor returns during the period. Here are some of Wells Fargo's top names for the next three months: Wells Fargo is bullish on Amazon , naming the stock as an overweight tactical idea. Wells Fargo's $211 price target implies about 17% upside from Tuesday's close. Despite a difficult start to the year that saw shares slump about 5%, Wells Fargo anticipates about 15% upside in store for the coffee chain retailer. Wells Fargo named Tesla among its four underweight ideas for the quarter, citing slowing delivery growth and dwindling demand.

Persons: Wells, Stocks, Ken Gawrelski, Wells Fargo's, INSM, Tiago Fauth, Zack Fadem, Colin Langan's Organizations: Insmed, Starbucks, Citigroup, Devon Energy Locations: Wells Fargo, Wells, North America, Monday's

☆ Credit Suisse gives its top stock picks for the second half
▼ + stars: | 2023-07-11 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

After a strong first half for the stock market, Credit Suisse has an idea to keep the gains going. Now, questions swirl around if the market can continue its ascent as the second half of 2023 kicks into high gear. Credit Suisse asked every one of its U.S. research analysts to name their top stock picks when looking at the next six to 12 months. His price target implies shares could rally nearly 35% over the next year. International Game Technology also made the list, with analyst Ben Chaiken expecting big upside ahead even after a strong first half.

Persons: Stocks, Alcoa, Curt Woodworth, Woodworth, Refinitiv, Ben Chaiken, Judah Frommer, Frommer, MasTec, Jamie Cook, — CNBC's Michael Bloom Organizations: Credit Suisse, Nasdaq, Technology

☆ Bank of America says these stocks have the most 'potential upside' this holiday season
▼ + stars: | 2022-12-10 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Analysts at Bank of America named five stocks this week that they say every investor must own heading into 2023. CNBC Pro combed through Bank of America research looking for stocks with major upside potential. Netflix Shares of Netflix are down 46.8% this year, but analyst Jessica Reif Ehrlich is standing by the streaming giant. Kroger Kroger shares have gained nearly 2.6% this year, but the stock has a lot more room to run, according to analyst Robert Ohmes. ... We rate Solo Brands' shares Buy as we believe its unique platform strategy should enable its high growth Leisure brands."

☆ This biotech stock can jump more than 90%, Barclays says
▼ + stars: | 2022-12-08 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Little-known Insmed could take off as one of its drugs with conditional approval and another in development show promise, according to Barclays. Analyst Leon Wang initiated the stock as overweight with a price target of $37, which presents a 94.9% upside from Wednesday's close. The company focuses on pulmonology-focused commercial biotech, with two major medications for bronchiectasis, which is when airways in lungs are widened, and a lung disease. Assuming strong data out of the third trial, Wang said the medication could hit the market in 2025. He said Insmed will likely surpass sales guidance, which was already set for a 30% year-over-year increase, in 2022.

☆ Here are Thursday's biggest analyst calls: Amazon, Chevron, Chipotle, Lowe's, Hershey, AT&T & more
▼ + stars: | 2022-12-08 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Wall Street's biggest calls on Thursday: Bank of America reiterates Chevron as buy Bank of America said it's standing by its buy rating on the oil and gas giant after it announced its 2023 capital budget on Wednesday. JPMorgan upgrades Vulcan Materials to overweight from neutral JPMorgan said risks for the construction materials company are already priced in. UBS initiates Shopify as sell UBS said it's concerned about increasing competition. UBS upgrades Hershey to buy from neutral UBS said it's becoming bullish on the chocolate and candy maker's long-term growth. Bank of America reiterates Lowe's as buy Bank of America said shares of Lowe's remain attractive.

Search resuls for: "Insmed"

11 mentions found